Literature DB >> 2874111

Loss of susceptibility to complement lysis in Entamoeba histolytica HM1 by treatment with human serum.

J Calderon, R Tovar.   

Abstract

Entamoeba histolytica HM1, exposed to a series of treatment with normal human serum (NHS), progressively lost susceptibility to complement lysis. Trophozoites were incubated daily with unheated or heat-inactivated NHS for 2 hr at 36 degrees, starting with 10% v/v serum and increasing by 5% every 3 days up to 40% NHS. Resistance to complement lysis was also obtained with two different HM1 clones but not with the low virulent strain HK9. Induction of resistance dependent on the number of NHS treatments, with a maximal 50% reduction occurring after 11 treatments. Susceptibility to complement-dependent lysis was regained 6 weeks after serum treatments were terminated, suggesting that resistance to lysis was an acquired rather than a genetic property.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874111      PMCID: PMC1453474     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes.

Authors:  E Engvall; K Jonsson; P Perlmann
Journal:  Biochim Biophys Acta       Date:  1971-12-28

2.  Clonal growth of Entamoeba histolytica and other species of Entamoeba in agar.

Authors:  F D Gillin; L S Diamond
Journal:  J Protozool       Date:  1978-11

3.  A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba.

Authors:  L S Diamond; D R Harlow; C C Cunnick
Journal:  Trans R Soc Trop Med Hyg       Date:  1978       Impact factor: 2.184

4.  Activation of the alternative pathway of complement by Entamoeba histolytica.

Authors:  L Ortiz-Ortiz; R Capin; N R Capin; B Sepúlveda; G Zamacona
Journal:  Clin Exp Immunol       Date:  1978-10       Impact factor: 4.330

5.  Comparative study of the antibody response in amebiasis. Persistence after successful treatment.

Authors:  I M Krupp; S J Powell
Journal:  Am J Trop Med Hyg       Date:  1971-05       Impact factor: 2.345

6.  Comparison of intradermal and serologic tests for the diagnosis of amebiasis.

Authors:  S E Maddison; I G Kagan; R Elsdon-Dew
Journal:  Am J Trop Med Hyg       Date:  1968-07       Impact factor: 2.345

7.  Entamoeba histolytica: collagenolytic activity and virulence.

Authors:  M L Muñoz; M Rojkind; J Calderón; M Tanimoto; S Arias-Negrete; A Martínez-Palomo
Journal:  J Protozool       Date:  1984-08

8.  [Determination of the alternative complement pathway in patients with amebic liver abscess].

Authors:  M R Capin; M Jiménez; G Zamacona; L Ortíz-Ortíz
Journal:  Arch Invest Med (Mex)       Date:  1978

9.  Immunoglobulin and complement levels in cases of invasive amoebiasis.

Authors: 
Journal:  Indian J Med Res       Date:  1978-02       Impact factor: 2.375

10.  An ion-channel forming protein produced by Entamoeba histolytica.

Authors:  E C Lynch; I M Rosenberg; C Gitler
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more
  10 in total

Review 1.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 2.  Complement evasion by parasites: search for "Achilles' heel".

Authors:  Z Fishelson
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Intestinal invasion by Entamoeba histolytica.

Authors:  Shahram Solaymani-Mohammadi; William A Petri
Journal:  Subcell Biochem       Date:  2008

4.  Entamoeba histolytica rhomboid protease 1 has a role in migration and motility as validated by two independent genetic approaches.

Authors:  Elena Rastew; Laura Morf; Upinder Singh
Journal:  Exp Parasitol       Date:  2015-04-15       Impact factor: 2.011

5.  Comparative genomic hybridizations of Entamoeba strains reveal unique genetic fingerprints that correlate with virulence.

Authors:  Preetam H Shah; Ryan C MacFarlane; Dhruva Bhattacharya; John C Matese; Janos Demeter; Suzanne E Stroup; Upinder Singh
Journal:  Eukaryot Cell       Date:  2005-03

6.  Inhibition of the complement membrane attack complex by the galactose-specific adhesion of Entamoeba histolytica.

Authors:  L L Braga; H Ninomiya; J J McCoy; S Eacker; T Wiedmer; C Pham; S Wood; P J Sims; W A Petri
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Complement resistance of pathogenic Entamoeba histolytica mediated by trypsin-sensitive surface component(s).

Authors:  C Hamelmann; B Urban; B Foerster; R D Horstmann
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

8.  Trogocytosis by Entamoeba histolytica Mediates Acquisition and Display of Human Cell Membrane Proteins and Evasion of Lysis by Human Serum.

Authors:  Hannah W Miller; Rene L Suleiman; Katherine S Ralston
Journal:  mBio       Date:  2019-04-30       Impact factor: 7.867

9.  Plasma membrane damage repair is mediated by an acid sphingomyelinase in Entamoeba histolytica.

Authors:  Fátima Ramírez-Montiel; Claudia Mendoza-Macías; Sairy Andrade-Guillén; Ángeles Rangel-Serrano; Itzel Páramo-Pérez; Paris E Rivera-Cuéllar; B Liliana España-Sánchez; Gabriel Luna-Bárcenas; Fernando Anaya-Velázquez; Bernardo Franco; Felipe Padilla-Vaca
Journal:  PLoS Pathog       Date:  2019-08-28       Impact factor: 6.823

10.  Complement is a rat natural resistance factor to amoebic liver infection.

Authors:  Alfonso Olivos-García; Mario Nequiz; Scarlet Liceaga; Edith Mendoza; Porfirio Zúñiga; Azucena Cortes; Gabriel López-Velázquez; Sergio Enríquez-Flores; Emma Saavedra; Ruy Pérez-Tamayo
Journal:  Biosci Rep       Date:  2018-10-02       Impact factor: 3.840

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.